Findings

What do systematic reviews say?

7 questions · 7 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 0 · 0%Moderate 3 · 42.9%High 1 · 14.3%

Anticoagulant vs different dose of the same anticoagulant

Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs antiplatelet agent

Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs placebo or no treatment

Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.25 [0.08, 0.79]
3 studies · 1009 participants
Moderate

Anticoagulant vs no treatment

Pulmonary embolism · people hospitalised with COVID‐19

It is very uncertain whether anticoagulants changes pulmonary embolism compared with no treatment (very low certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 24.19 [3.31, 176.53]
1 study · 1403 participants
Very low

Higher‐dose anticoagulants vs lower‐dose anticoagulants

Pulmonary embolism · people hospitalised with COVID‐19

Higher‐dose anticoagulants probably leads to lower pulmonary embolism compared with lower‐dose anticoagulants (moderate certainty).

1 finding from 1 review

Anticoagulants for people hospitalised with COVID‐19: a rapid review 2022 · Cochrane Headline outcomes only
RR 0.46 [0.31, 0.7]
4 studies · 4360 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.48 [0.24, 0.98]
3 studies · 1440 participants
Moderate

Anticoagulant vs control

Symptomatic PE · acute presumed ischaemic stroke

Summary of findings table ‐ Anticoagulant leads to lower symptomatic pulmonary embolism during treatment period compared with control (high certainty).

1 finding from 1 review

Anticoagulants for acute ischaemic stroke 2021 · Cochrane Headline outcomes only
OR 0.6 [0.44, 0.81]
14 studies · 22544 participants
High